Ergoresearch Inc. Announces the Appointment of Its New V-P Finance

MONTREAL, QUEBEC--(Marketwire - October 23, 2009) - Ergoresearch Ltd “Ergoresearch” (TSX VENTURE: ERG), just days before announcing its financial performance for the year ended on June 30, 2009, is pleased to announce the appointment to its management team of Mr. Michel Pare as Vice-President Finance.

Mr. Pare previously acted as Financial Controller for General Motors Canada from 1990 to 1997, Director of the Finance Department and Chief Accountant for an international company that manufacture and distribute lighting fixtures, from 1997 to 2002 and also acted as Financial Controller (administrative director) as well as Controller for divisions of this same group from 2002 to 2009.

During the years, Mr. Pare developed an expertise in business management, managing human, material and financial resources, as well as in mergers, acquisitions and integrating businesses. He also negotiated partnerships and strategic alliances and has experience with the Chinese market. He also contributed in the analysis, development and implementation of software and technology solutions.

Mr. Sylvain Boucher President & CEO explains : “This appointment couldn’t come at a better time in the Company’s growth. Mr. Pare brings the experience and competence so essential for the Company to pursue its growth strategy.”

Mr. Pare added : “The challenge of joining a fast growing enterprise that skillfully integrates technologies in an industry of necessity such as healthcare, is most stimulating.”

Ergoresearch will announce on Monday, October 26, 2009, its financial results for the fiscal year ended June 30, 2009.

Ergoresearch Ltd (www.ergorecherche.com) through its subsidiaries (www.cliniquedupiedequilibre.com ) and (www.orthoconcept.com ), is a leading general and foot orthotics manufacturer as well as being on the leading edge of durable medical equipment development in the orthopaedic industry. The Company owns patented technologies that confer competitive advantages in the industry and relies on its undeniable knowledge of consolidation in the healthcare industry.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.